International Trade Bulletin - Volume 1, Issue 1
Client Alert | 2 min read | 03.20.06
Inside this issue:
- CHINA IN THE SPOTLIGHT
- EUROPE IN THE SPOTLIGHT
- DUTY RECOVERY : Many importers and manufacturers pay unnecessary duty on imported merchandise, either directly or as a cost of procured materials
- BILATERAL TRADE: The proposed U.S. – Korea FTA will be the most commercially significant FTA the U.S. has negotiated since NAFTA
- FOREIGN INVESTMENTS: New Indian investment rules allow foreign retailers to set up majority-owned stores in India – a high-growth market eyed by foreign retailers for years
- AIR TRANSPORT: Controversial U.S. DOT proposal to attract investment in the U.S. Airlines draws fire from both sides of the pond rather than hope for Open Skies
- SANCTIONS: The Office of Foreign Assets Control (“OFAC”) of the U.S. Department of the Treasury has issued an interim final rule outlining a new set of enforcement procedures
- NAFTA: NAFTA provisions on “regional value content” (RVC) calculation causes serious problems for related parties
- DUTY SUSPENSION: The Miscellaneous Tariff Bill (MTB) may be more relevant to your business than it sounds - at least if you are an importer of products that American factories do not produce domestically
- INTERNATIONAL IP PROTECTION: Elements of India’s new patent law which took effect in 2005 have prevented Novartis from obtaining a patent for its cancer drug “Gleevec”
Insights
Client Alert | 2 min read | 05.12.25
“Confirm You’re Not a Robot”: AI-Written Briefs Could Lead to Sanctions
On May 7, 2025, GAO issued a decision in Raven Investigations & Security Consulting, LLC, B-423447, warning the bid protest bar that artificial intelligence (“AI”)-based tools utilized without proper oversight may result in severe consequences, including dismissal of the protest and sanctions.
Client Alert | 3 min read | 05.12.25
EU Retaliatory Trade Measures Against the U.S. – Public Consultation
Client Alert | 2 min read | 05.09.25
FDA Seeks Stakeholder Consultation on Prescription Drug User Fee Reauthorization
